Injective (INJ) is currently trading at $3.17, reflecting a 3.59% increase over the past 24 hours. The price action has stayed within a daily range of $2.95 to $3.17, indicating a relatively stable trading environment with limited volatility.

Volume for INJ stands at approximately $39.4 million, contributing to a 12.48% ratio of volume to market cap. This suggests healthy trading activity, supporting the recent price increase and showing investor interest, which could signal a potential continuation of this upward trend.

Technical indicators show that the 1-hour RSI is at 78, indicating overbought conditions in the short term. However, the 7-day RSI is neutral at 52, suggesting that the price has room to move either way, and the momentum may stabilize before any further upward movement.

Moving averages indicate bullish trends, with the 8 SMA at $3.02 and a notable gain of 5.10%. The 13 SMA and 21 SMA are also trending upwards, reinforcing positive sentiment among traders, while the 55 SMA ($3.10) and 144 SMA ($3.12) are showing slower but steady growth.

Over the past 14 days, INJ has increased by approximately 4.41%, indicating a generally positive trend in the medium term. The longer-term view, however, reveals that the asset is still significantly below its all-time high of $52.62, reached in March 2024, suggesting considerable upside potential if bullish momentum continues.

Based on the current analysis of technical indicators, price action, and volume metrics, I recommend a Buy rating for INJ. The combination of healthy trading volume, positive moving averages, and reasonable price performance over various time frames supports this recommendation, despite the short-term overbought condition indicated by the 1-hour RSI.